Oxidised low-density lipoprotein (LDL) cholesterol is vasoconstrictor, mitogenic, pro-inflammatory and thrombogenic. This review summarises the evidence for its vasoconstrictor properties. LDL cholesterol potentiates noradrenaline vasoconstriction in the peripheral vasculature, and in the coronary, cerebral and renal vascular beds. There is also blunting of endothelium-dependent vasodilator responses to acetylcholine. These effects are reversed, or at least reduced, by lipid-lowering agents and (because LDL cholesterol
Introduction
Elevated low-density lipoprotein (LDL) cholesterol (and a low high-density lipoprotein (HDL) cholesterol) are well recognised as major risk factors for the development of atherosclerosis, predisposing to major cardiovascular catastrophes like myocardial infarction and stroke. The 'classical' view of the pathogenesis of this process is that LDL cholesterol is a major component of the atheromatous plaque, and the hypercholesterolaemia is a significant risk factor for vascular morbidity and mortality by its incorporation into the plaque. However, in the past decade or so, LDL cholesterol has been found to have another role as well, a more dynamic role as a modulator of vascular function, vasoconstrictor, mitogenic, pro-inflammatory, thrombogenic and chemotaxic. This brief review will be confined to the vasoconstrictor effects of LDL cholesterol.
Increased noradrenaline vasoconstrictor sensitivity
Many years ago we were investigating the mechanism of hepato-renal failure, and in particular, were searching for the circulating factor which potentiated noradrenaline (NA) vasoconstriction of renal cortical resistance vessels. As part of this search, we used a very simple experimental set-up which was a length of rabbit femoral artery perfused by saline at 37°C via a constant flow peristaltic pump. The upstream pressure, measured by a pressure transducer, was an index of the resistance of the artery. Dose response curves, describing the effect of increasing doses of NA on the femoral artery resistance, could be constructed. We constructed the NA dose-response curves in the presence of each of the components of plasma which we thought were elevated in liver failure, and which we thought might be important in potentiating the vasoconstrictor effects of NA. The only one which did this was LDL cholesterol; which caused an impressive leftward shift in the curve, and then returned back towards normal when the system was later perfused with cholesterol-free saline. This was the first demonstration of the action of LDL cholesterol to potentiate the vasoconstrictor action of NA, and the first demonstration of a more dynamic, vasoactive action of the lipoprotein on the vasculature. 1 We subsequently showed the same effect in intact animals in the renal, cerebral and coronary vascular beds, 2,3 and in both anesthetised and conscious animals, including rabbits and baboons; in all of these there was a leftward shift of the vasoconstrictor response to NA, returning toward, but not always all the way, back to normal after the LDL cholesterol was normalised. The same phenomenon was seen in animals made hypercholesterolaemic by feeding a high cholesterol diet for a period of time long enough to increase serum LDL cholesterol values many-fold, but too short to see any morphological changes in the vessels.
Decreased acetylcholine vasodilator sensitivity
It has also been shown that LDL cholesterol decreases acetylcholine vasodilator sensitivity. AcetylEffects of LDL cholesterol on vascular function C Rosendorff S27 choline (ACh) dilates vessels by stimulating the release of nitric oxide (NO) from endothelial cells, and is therefore a simple way to study endotheliummediated vasodilator responses in health and disease. Impairment of endothelial function can be expected to blunt the vasodilator response to ACh. One such experiment was reported by Gerhard et al. 4 The slope of the dose-response curve (dose of methacholine, an ACh analog vs forearm blood flow) declined with age in a group of 119 otherwise healthy human subjects ranging in age from 19 to 69 years, whereas the vasodilator response to nitroprusside, which acts directly on the vascular smooth muscle, was unimpaired. On univariate analysis, the significant predictors of the decline in endotheliumdependent vasodilatation were age, total cholesterol and LDL cholesterol, suggesting that these three factors are associated with endothlial damage. Similar results have been described in diseased arteries. In young adults with insulin-dependent diabetes mellitus, brachial artery reactive hyperaemia (endothelium-dependent) was significantly impaired compared with matched non-diabetic control subjects, out of proportion to any impairment of glyceryl trinitrate (endothelium independent) responses. On multivariate analysis, the flowmediated dilation was inversely related to LDL cholesterol levels. 5 In 26 patients with coronary atherosclerosis but no focal stenosis by quantitative coronary ultrasound, ACh infused into the coronary artery was vasodilator if the atherosclerotic wall thickening was minimal, and vasoconstrictor if it was severe. Again, a multivariate analysis showed that abnormal (vasoconstrictor) responses to ACh was associated with high LDL levels, as well as the degree of wall thickness and hypertension, and inversely related to HDL cholesterol. 6 In another study in subjects with total cholesterol levels between 175 and 215 mg/dl, cholesterol-lowering improved flow-mediated brachial artery vasodilation. 7 Are these effects reversible if the cholesterol levels are normalised? In a Japanese study, 8 seven patients with hypercholesterolaemia, defined as a LDL cholesterol level greater than the 75th percentile for that population, had a mean total cholesterol level of 195 mg/dl and a mean LDL level of 142 mg/dl. After apheresis (perfusion of their plasma through dextran sulfate cellulose beads), corresponding values were 75 and 38 mg/dl. The depressed forearm blood flow response to infused ACh (endothelium-dependent) was significantly augmented, ie normalised, after apheresis, with no change in the endothelium-independent vasodilator response to sodium nitroprusside.
To summarise thus far:
(1) LDL cholesterol sensitises vessels to the vasoconstrictor effects of vasoconstrictor agents like noradrenaline. (2) What is the mechanism of the LDL cholesterol inhibition of ACh vasodilation? Wang et al (1996) 9 showed that the administration of L-arginine, the NO precursor, reduced the impairment of ACh vasodilatation in iliac arteries from hypercholesterolaemic rabbits. In addition, they found that arginine diminished the vascular lesions induced by balloon injury. In another study 10 in hypercholesterolaemic rabbits, the impaired vasodilator response of the abdominal aorta to ACh was normalised in animals fed L-arginine. Also, histomorphometric measurements showed a marked decrease in intimal thickening in L-arginine supplemented hypercholesterolaemic animals. Lastly, in hypercholesterolaemic patients, the impairment of serotonin-induced vasodilatation (also endothelium-dependent) of forearm vessels was normalised by either lipid-lowering or by intra-arterial L-arginine. 11 Nitric oxide synthase is down-regulated by oxidised LDL-cholesterol; this effect was prevented by simvastatin and lovastatin. 12 There is therefore very solid evidence that at least one mechanism in the impairment of endotheliumdependent vasodilatation in hypercholesterolaemia is impaired NO production or release or both.
Effects of anti-oxidants
Since the adverse effects of cholesterol on vascular structure and function are due to oxidised LDL-cholesterol, it might be predicted that antioxidants would prevent these actions. In rabbits made hypercholesterolaemic by 8 weeks of cholesterol feeding, there was impairment of the coronary vasodilator response to ACh, but co-administration of vitamin E with the cholesterol produced a dose response to ACh intermediate between the cholesterol fed animals and the controls. 13 Ting et al 14 showed that an infusion of vitamin C into the brachial artery improved the forearm blood vasodilator response to infused methacholine, but not nitroprusside, in 11 hypercholesterolaemic subjects. In two studies, 15, 16 both reported in the same issue of The New England Journal of Medicine in 1995, the effects of cholesterol lowering and of anti-oxidant therapy on coronary endothelial function was studied in patients with coronary artery disease and hypercholesterolaemia. Treasure et al 15 found that intracoronary ACh caused coronary vasoconstriction in control patients, but not in patients after 5. months of lovastatin therapy. In the other study 16 patients were allocated to four groups; a control group, the American Heart Association Step 1 diet, lovastatin plus cholestyramine (lipid lowering), and lovastatin plus probucol (lipid lowering and anti-oxidant). There was no difference between the control and the diet group in reversing the coronary vasoconstrictor effect of intracoronary ACh, but less vasoconstriction in the lovastatin plus cholestyramine group, and least in the patients taking lovastatin plus the anti-oxidant probucol.
All of these studies would suggest that antioxidant therapy is beneficial in reversing the deleterious effects of oxidised LDL-cholesterol on endothelium-dependent vasodilator responses. It could therefore be expected that these concepts could be translated into clinical benefit, but it must be said that the clinical trials of anti-oxidant agents in cardiovascular disease 17 have produced disappointing results.
Conclusion
Oxidised LDL cholesterol modulates vascular responses to a variety of vasoactive neurohormones. In particular, LDL cholesterol blunts vasodilator responses to ACh, and in some atherosclerotic models ACh responses may even be vasoconstrictor. These actions are at least partially reversed by cholesterol-lowering drugs, and by anti-oxidants. One mechanism of this effect is endothelial NO, the synthesis and release of which is inhibited by LDL cholesterol.
LDL cholesterol has other, deleterious actions on the vasculature. It is mitogenic, stimulating vascular hypertrophy via a number of growth factors, such as ␣ (␣-fibroblast growth factor) and PDGF (plateletderived growth factor), pro-inflammatory and prothrombotic. All of this underscores not only the importance of identifying and treating all patients with hypercholesterolaemia, but also to study the effect of lipid lowering on vascular structure and function and on cardiovascular morbidity and mortality in patients with 'normal' levels of LDL cholesterol.
